NCIRE - The Veterans Health Research Institute Home  |  Sitemap  |  Intranet  |  UltiPro   Visit our Facebook page  Visit our Twitter page  Visit our LinkedIn page

Give Now
About NCIRE Participate in Research Support Our Mission Careers at NCIRE Contact Us
Veterans Health
Research at NCIRE

NCIRE-The Veterans Health Research Institute is the leading private nonprofit institute devoted to Veterans health research in the United States. Our mission is to advance Veterans health through research.

We support the work of some of the nation's foremost physicians and scientists at the San Francisco Veterans Affairs Medical Center, the premier biomedical research facility in the VA system. All have faculty appointments at the University of California, San Francisco, which has its own proud traditions of research and patient care. We also partner with the U.S. Department of Defense to support health research on behalf of our men and women in the Armed Forces.

Those who have served in uniform have given their best for their country. In return, we believe that they deserve nothing less than the best health care research we can provide.

Contact Us
Give Now
Matthew R. Cooperberg, MD, MPH

Staff Physician, Urology Service, SFVAHCS
Clinical Instructor of Urology, UCSF


Tailoring Cancer Treatment to Severity of Disease

Dr. Cooperberg has several clinical research interests in urologic oncology, focusing primarily on prostate and renal cancer. He is focused in particular on risk-adapted treatment strategies, which assign intensity of therapy according to risk of death from the diagnosed disease or to initial response to therapy. Through work with the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), the UCSF Urologic Outcomes Data Base (UODB), and other data sources, he has published analyses on health services utilization, cancer risk assessment, and both oncologic and health-related quality of life outcomes. He led the development of the Cancer of the Prostate Risk Assessment (CAPRA) score for prostate cancer risk stratification, an instrument which has now been extensively validated among over 10,000 prostate cancer patients in the United States and Europe.

To see Dr. Cooperberg on Pub Med, click here.